Sonoma Pharmaceuticals Sustainability Profile
Sonoma Pharmaceuticals, Inc., headquartered in the United States, is a leading player in the pharmaceutical industry, specialising in innovative therapies for dermatological and ophthalmic conditions. Founded in 2014, the company has made significant strides in developing unique formulations that leverage the power of hypochlorous acid, setting it apart in the market. With a focus on wound care, skin care, and eye care, Sonoma's core products, including its patented Alevicyn® and Alevicyn® Eye Drops, are designed to promote healing while minimising irritation. The company has established a strong market position, recognised for its commitment to quality and efficacy. Sonoma Pharmaceuticals continues to expand its operational reach, aiming to improve patient outcomes globally through its advanced therapeutic solutions.
DitchCarbon Score
How does Sonoma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sonoma Pharmaceuticals's score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sonoma Pharmaceuticals's reported carbon emissions
Sonoma Pharmaceuticals, headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and formal commitments suggests that Sonoma Pharmaceuticals may not yet have established a comprehensive framework for addressing its carbon footprint or climate impact. As the industry increasingly prioritises sustainability, it will be essential for the company to consider developing measurable climate commitments and reduction initiatives to align with global standards and expectations.
How Carbon Intensive is Sonoma Pharmaceuticals's Industry?
How Carbon Intensive is Sonoma Pharmaceuticals's Location?
Sonoma Pharmaceuticals's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Sonoma Pharmaceuticals has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
